Kestra Medical reports strong 2026 results; guides robust 2027 growth
Jul 14, 2026, 4:04 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
Strong top-line growth, improved gross margins, and a 44% FY27 revenue guide imply a clearer path to earnings power and cash flow improvement. The market may re-rate KMTS on execution milestones (FDA studies, algorithm updates, collaborations) despite ongoing losses. Historical peers have seen rallies on margin expansion and solid guidance, but downside risk remains if cash burn accelerates.
AI summary
What happened, with direct paths to the underlying reporting
Kestra Medical Technologies posted a strong fiscal 2026 with 66% quarterly revenue growth and a higher gross margin (Q4 at 54.8%, full-year 51.4%). It guiding FY27 revenue of $137M signals sustained growth, supported by FDA post-approval updates, a new algorithm, and a Biobeat collaboration. These catalysts could lift KMTS sentiment and valuation as profitability paths improve.
Q4 2026 revenue $28.6M, +66% YoY.
FY26 revenue $95.1M, +59%.
Gross margin: Q4 54.8%, FY26 51.4%.
FY27 revenue guidance $137M, +44%.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
